Drugs / Leflunomide
Leflunomide
also known as
LEF · SU101 · Arava · Arthfree · HWA-486 · L04AA13 · Leflunomid · Leflunomida · +9 more
Small molecule targets DHODH via inhibition
Regulatory milestones approvals, filings & regulatory actions · 4 recorded
| Milestone | Jurisdiction | Brand | Indication | Date | Sentence it was read from |
|---|---|---|---|---|---|
| Label expansions (2) | US (FDA) | ARAVA | — | 2003-06-13 – 2004-03-05 | fda.gov ↗ |
| Approved | EU (EMA) | Arava | — | 1999-09-02 | europa.eu ↗ |
| Approved | US (FDA) | ARAVA | — | 1998-09-10 | fda.gov ↗ |
Trials 61 · started per year
today
US approved 1998
EU approved 1999
1
2
2
5
5
1
1
3
2
1
3
2
1
1
4
7
4
4
7
3
2
1997199819992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT04370483 | Oct 2020 → Nov 2026 expected | smoldering plasma cell myeloma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 113 trials | ||||||
| Phase 1 | NCT06454383 | May 2024 → Nov 2026 expected | pancreatic ductal adenocarcinoma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04997993 | Dec 2023 → Jul 2027 expected | Her2-receptor negative breast cancer | Deborah Doroshow | Recruiting | No outcome recorded |
| Phase 1 | NCT05443425 | Jun 2023 → Jan 2027 expected | acute graft versus host disease, hematopoietic and lymphoid system neoplasm | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 1 | NCT04212416 | May 2020 → Jun 2027 expected | chronic graft versus host disease | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04361214 | May 2020 → Jan 2022 | COVID-19 | University of Chicago | Terminated | No outcome recorded |
| Phase 1 | NCT01611675 | Jul 2012 → Jan 2014 | melanoma | Massachusetts General Hospital | Terminated | No outcome recorded |
| Phase 1 | NCT00101374 | Jan 2005 → May 2008 | HIV infectious disease | National Institute of Allergy and Infectious Diseases (NIAID) | Completed | No outcome recorded |
| Phase 1 | NCT00653003 | Dec 2003 → Jan 2004 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00652665 | Jun → Jul 2003 | — | Par Pharmaceutical, Inc. | Completed | No outcome recorded |
| Phase 1 | NCT00946686 | Sep 2002 | psoriatic arthritis | Sandoz | Completed | No outcome recorded |
| Phase 1 | NCT00834418 | Jun → Jul 2002 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00834405 | Apr → May 2002 | — | Teva Pharmaceuticals USA | Completed | No outcome recorded |
| Phase 1 | NCT00001573 | Mar 1997 → May 2000 | glioma, sarcoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT06923488 | Jul 2025 → Oct 2027 expected | myelodysplastic syndrome | West Virginia University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT05937191 | Jun 2023 → Dec 2026 expected | pulmonary hemosiderosis | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04532372 | Jan → Aug 2021 | COVID-19, cancer, hematopoietic and lymphoid cell neoplasm | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 1/2 | NCT03709446 | Apr 2019 → Nov 2025 | triple-negative breast carcinoma | Joseph Sparano | Completed | No outcome recorded |
| Phase 1/2 | NCT02509052 | Dec 2015 → Sep 2018 | plasma cell myeloma | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 217 trials | ||||||
| Phase 2 | NCT07138898 | Dec 2025 → Jan 2028 expected | rheumatic disorder | NYU Langone Health | Recruiting | No outcome recorded |
| Phase 2 | NCT07709013 | Oct 2024 → Apr 2029 expected | hematopoietic and lymphoid cell neoplasm | Tata Memorial Centre | Recruiting | No outcome recorded |
| Phase 2 | NCT06229340 | Oct 2023 → Oct 2026 expected | colorectal cancer, lung cancer, malignant pancreatic neoplasm, melanoma +1 | N.N. Petrov National Medical Research Center of Oncology | Recruiting | No outcome recorded |
| Phase 2 | NCT04932564 | Sep 2023 → Jun 2024 | chronic graft versus host disease, musculoskeletal system disorder | Tata Memorial Centre | Terminated | No outcome recorded |
| Phase 2 | NCT05014646 | Mar 2022 → Jan 2027 expected | smoldering plasma cell myeloma | City of Hope Medical Center | Active not recruiting | No outcome recorded |
| Phase 2 | NCT05113004 | Jan 2022 → Apr 2025 overdue | Sjogren syndrome | Assistance Publique - Hôpitaux de Paris | Recruiting | No outcome recorded |
| Phase 2 | NCT04463615 | May → Jul 2021 | lymphoproliferative syndrome | City of Hope Medical Center | Completed | No outcome recorded |
| Phase 2 | NCT04508790 | Nov 2020 → Feb 2027 expected | plasma cell myeloma | City of Hope Medical Center | Recruiting | No outcome recorded |
| Phase 2 | NCT06540937 | Jul 2020 → Dec 2024 overdue | neuroendocrine neoplasm | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | Recruiting | No outcome recorded |
| Phase 2 | NCT03952832 | Dec 2019 → Jun 2021 | smoldering plasma cell myeloma | City of Hope Medical Center | Withdrawn | No outcome recorded |
| Phase 2 | NCT02532777 | Aug 2015 → Jul 2020 | immunoglobulin A vasculitis | Nanjing Children's Hospital | Unknown | No outcome recorded |
| Phase 2 | NCT01620268 | Jul 2012 → Jun 2018 | — | Changzheng-Cinkate | Terminated | No outcome recorded |
| Phase 2 | NCT00802243 | Sep 2007 → ? | bullous pemphigoid | University Hospital, Limoges | Unknown | No outcome recorded |
| Phase 2 | NCT00637819 | Jan 2003 → Jul 2004 | systemic lupus erythematosus | Sanofi | Completed | No outcome recorded |
| Phase 2 | NCT00244179 | Jan 2003 → ? | reactive arthritis | Charite University, Berlin, Germany | Unknown | No outcome recorded |
| Phase 2 | NCT00001863 | Mar 1999 → Feb 2003 | uveitis | National Eye Institute (NEI) | Completed | No outcome recorded |
| Phase 2 | NCT00003775 | Dec 1998 → May 2006 | central nervous system neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT00268567 | Oct 2002 → ? | lupus nephritis | Peking University | Completed | No outcome recorded |
| Phase 2/3 | NCT00004071 | Aug 1999 → Sep 2007 | prostate cancer | Pfizer | Completed | No outcome recorded |
| Phase 34 trials | ||||||
| Phase 3 | NCT04610476 | Oct 2020 → Oct 2024 | psoriatic arthritis, substance withdrawal syndrome | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT02779114 | Jan 2009 → Dec 2017 | rheumatoid arthritis | University of Erlangen-Nürnberg Medical School | Unknown | No outcome recorded |
| Phase 3 | NCT00596206 | Dec 2007 → Oct 2009 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT00003293 | Feb 1998 → May 2001 | central nervous system neoplasm | Pfizer | Completed | No outcome recorded |
| Phase 49 trials | ||||||
| Phase 4 | NCT07428551 | Mar 2024 → Dec 2025 | polyarticular juvenile idiopathic arthritis | Bangladesh Medical University | Completed | No outcome recorded |
| Phase 4 | NCT05626348 | Dec 2021 → Jun 2025 overdue | rheumatoid arthritis | Qilu Hospital of Shandong University | Recruiting | No outcome recorded |
| Phase 4 | NCT04020328 | Sep 2019 → Mar 2022 | IgA glomerulonephritis, chronic kidney disease | Shenzhen Second People's Hospital | Unknown | No outcome recorded |
| Phase 4 | NCT03739853 | May 2019 → Oct 2024 | psoriatic arthritis | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT02703194 | Mar 2016 → Jan 2019 | immunoglobulin G4-related sclerosing disease | Chinese PLA General Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01172639 | Feb 2009 → Jun 2015 | rheumatoid arthritis | P. Verschueren | Completed | No outcome recorded |
| Phase 4 | NCT00280644 | Apr 2004 → ? | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00563849 | May 2003 → Aug 2004 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT00451971 | Mar 2002 → ? | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase not applicable10 trials | ||||||
| — | NCT05605587 | May 2023 → Jan 2026 | multiple endocrine neoplasia type 1 | University Hospital, Basel, Switzerland | Terminated | No outcome recorded |
| — | NCT05937880 | Jan 2023 → Jun 2027 expected | immunoglobulin A vasculitis | Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Recruiting | No outcome recorded |
| — | NCT05789017 | Jul 2022 → Dec 2024 | autoimmune disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT05789030 | Jul 2022 → Apr 2026 overdue | autoimmune disease | Peking Union Medical College Hospital | Recruiting | No outcome recorded |
| — | NCT04737343 | Jun 2021 → Nov 2024 | anti-neutrophil cytoplasmic antibody-associated vasculitis | Chinese SLE Treatment And Research Group | Unknown | No outcome recorded |
| — | NCT04124861 | Jun 2020 → Dec 2022 | autoimmune disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT03715699 | Jul 2018 → Dec 2020 | autoimmune disease | Peking Union Medical College Hospital | Unknown | No outcome recorded |
| — | NCT01617590 | May 2012 → Dec 2013 | rheumatoid arthritis | Shanxi Medical University | Unknown | No outcome recorded |
| — | NCT01172002 | Mar 2010 → Jun 2018 | lupus erythematosus, nephritis | RenJi Hospital | Unknown | No outcome recorded |
| — | NCT00684372 | May 2007 → May 2009 | end stage renal failure, polyomavirus infectious disease | Karolinska University Hospital | Unknown | No outcome recorded |
Also used as a comparator or background therapy in 48 trials
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT05247203 Background | May 2022 → Oct 2023 | systemic lupus erythematosus | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 28 trials | ||||||
| Phase 2 | NCT06753565 Background | Dec 2024 → Jun 2025 overdue | rheumatoid arthritis | German University in Cairo | Recruiting | No outcome recorded |
| Phase 2 | NCT06640309 Background | Dec 2023 → Jun 2025 overdue | rheumatoid arthritis | Ain Shams University | Recruiting | No outcome recorded |
| Phase 2 | NCT05447520 Background | Dec 2021 → Dec 2022 | rheumatoid arthritis | Noha Mansour | Completed | No outcome recorded |
| Phase 2 | NCT03863405 Background | Jan 2019 → Jan 2020 | rheumatoid arthritis | Ain Shams University | Unknown | No outcome recorded |
| Phase 2 | NCT02885610 Comparator | Dec 2015 → Jun 2019 | systemic lupus erythematosus | RemeGen Co., Ltd. | Completed | No outcome recorded |
| Phase 2 | NCT01225393 Background | Nov 2010 → Jul 2012 | rheumatoid arthritis | Genentech, Inc. | Completed | No outcome recorded |
| Phase 2 | NCT01033656 Comparator | Dec 2005 → Mar 2010 | adult-onset Still disease | University of Helsinki | Completed | No outcome recorded |
| Phase 2 | NCT00230035 Comparator | Sep 2005 → ? | systemic lupus erythematosus | National Institute of Allergy and Infectious Diseases (NIAID) | Withdrawn | No outcome recorded |
| Phase 2/32 trials | ||||||
| Phase 2/3 | NCT05871086 Background | May → Dec 2023 | juvenile idiopathic arthritis | Nourhan Elsherif | Unknown | No outcome recorded |
| Phase 2/3 | NCT05671497 Background | Nov 2022 → Oct 2024 | rheumatoid arthritis | Ain Shams University | Completed | No outcome recorded |
| Phase 319 trials | ||||||
| Phase 3 | NCT05007678 Comparator | Sep 2020 → Jul 2022 | COVID-19 | Ashford and St. Peter's Hospitals NHS Trust | Completed | No outcome recorded |
| Phase 3 | NCT03576794 Comparator | Mar 2019 → Nov 2022 | polymyalgia rheumatica | Elisabeth Brouwer | Unknown | No outcome recorded |
| Phase 3 | NCT02930343 Comparator | Sep 2016 → Aug 2018 | rheumatoid arthritis | Jawaharlal Institute of Postgraduate Medical Education & Research | Terminated | No outcome recorded |
| Phase 3 | NCT02873936 Background | Jul 2016 → Mar 2018 | rheumatoid arthritis | Gilead Sciences | Completed | No outcome recorded |
| Phase 3 | NCT02373202 Background | Feb 2015 → Nov 2016 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT02057250 Background | Mar 2014 → Feb 2015 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01941095 Background | Nov 2013 → Jul 2016 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT01768572 Background | Mar 2013 → Oct 2014 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01709578 Background | Oct 2012 → Mar 2015 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 3 | NCT01727193 Comparator | Sep 2012 → Oct 2021 | myasthenia gravis | First Affiliated Hospital, Sun Yat-Sen University | Completed | No outcome recorded |
| Phase 3 | NCT01342016 Comparator | Apr 2011 → May 2013 | lupus nephritis | Astellas Pharma Inc | Terminated | No outcome recorded |
| Phase 3 | NCT01256736 Background | Mar 2010 → Dec 2011 | rheumatoid arthritis | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT01211834 Comparator | Oct 2009 → Oct 2010 | rheumatoid arthritis | JW Pharmaceutical | Completed | No outcome recorded |
| Phase 3 | NCT03414502 Comparator | Dec 2007 → Mar 2028 expected | rheumatoid arthritis | University of Nebraska | Recruiting | No outcome recorded |
| Phase 3 | NCT00531817 Background | Oct 2007 → Jun 2009 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00476996 Background | May 2007 → Jan 2010 | rheumatoid arthritis | Genentech, Inc. | Terminated | No outcome recorded |
| Phase 3 | NCT00720798 Background | Sep 2005 → Apr 2013 | rheumatoid arthritis | Hoffmann-La Roche | Completed | No outcome recorded |
| Phase 3 | NCT00124982 Background | Apr 2005 → Aug 2009 | rheumatoid arthritis | Bristol-Myers Squibb | Completed | No outcome recorded |
| Phase 3 | NCT00579878 Comparator | Mar 2001 → Mar 2010 | rheumatoid arthritis | University of Nebraska | Completed | No outcome recorded |
| Phase 413 trials | ||||||
| Phase 4 | NCT03797872 Comparator | Apr 2019 → Jul 2020 | psoriatic arthritis | University of Oxford | Completed | No outcome recorded |
| Phase 4 | NCT04066803 Background | Aug 2018 → Jul 2020 | rheumatoid arthritis | Sun Yat-sen University | Unknown | No outcome recorded |
| Phase 4 | NCT03649061 Comparator | Jun 2018 → Jul 2022 | rheumatoid arthritis | P. Verschueren | Completed | No outcome recorded |
| Phase 4 | NCT03449758 Background | Mar 2018 → Jul 2019 | rheumatoid arthritis | Sanofi | Completed | No outcome recorded |
| Phase 4 | NCT02714634 Background | Mar 2016 → Mar 2029 expected | rheumatoid arthritis | University Hospital, Strasbourg, France | Recruiting | No outcome recorded |
| Phase 4 | NCT02878161 Background | Jan 2016 → Dec 2019 | rheumatoid arthritis | Fen Li | Unknown | No outcome recorded |
| Phase 4 | NCT02644499 Comparator | Dec 2015 → Feb 2017 | rheumatoid arthritis | Jawaharlal Institute of Postgraduate Medical Education & Research | Completed | No outcome recorded |
| Phase 4 | NCT02451748 Background | Aug 2015 → Sep 2017 | rheumatoid arthritis | University of Illinois at Chicago | Completed | No outcome recorded |
| Phase 4 | NCT02275299 Comparator | Sep 2013 → Feb 2016 | rheumatoid arthritis | Jiangsu Simcere Pharmaceutical Co., Ltd. | Unknown | No outcome recorded |
| Phase 4 | NCT02024334 Comparator | Jun 2013 → Jun 2014 | juvenile idiopathic arthritis | Mashhad University of Medical Sciences | Unknown | No outcome recorded |
| Phase 4 | NCT01659242 Comparator | Jul → Dec 2012 | rheumatoid arthritis | Singapore General Hospital | Terminated | No outcome recorded |
| Phase 4 | NCT01313208 Background | Mar 2011 → Feb 2013 | rheumatoid arthritis | Amgen | Completed | No outcome recorded |
| Phase 4 | NCT00422227 Comparator | Jun 2007 → Mar 2009 | rheumatoid arthritis | Wyeth is now a wholly owned subsidiary of Pfizer | Completed | No outcome recorded |
| Phase not applicable5 trials | ||||||
| — | NCT04542733 Comparator | Jun 2023 → Dec 2027 expected | disease related to solid organ transplantation, polyomavirus infectious disease | King Chulalongkorn Memorial Hospital | Active not recruiting | No outcome recorded |
| — | NCT02981979 Comparator | Dec 2016 → May 2022 | Takayasu arteritis | Jiang lindi | Completed | No outcome recorded |
| — | NCT01774877 Comparator | Jul 2013 → Jun 2014 | rheumatoid arthritis | The First Affiliated Hospital of Anhui University of Traditional Chinese Medicine | Completed | No outcome recorded |
| — | NCT01619176 Background | Oct 2012 → Dec 2014 | rheumatoid arthritis | Chinese Academy of Sciences | Completed | No outcome recorded |
| — | NCT01600521 Comparator | Nov 2004 → Apr 2011 | rheumatoid arthritis | University of Minnesota | Completed | No outcome recorded |
Press releases naming this drug 1 release
| Date | Issuer | Release |
|---|---|---|
| 2005-09-14 | Teva Branded Pharmaceutical Products R&D, Inc. | Teva Announces Approval of Leflunomide Tablets tevapharm.com ↗ |
Evidence & citations 22 cited values
Every value below carries the sentence it was read from. 111 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | leflunomide | “Standard therapy comprises any of the following (alone or in combination): corticosteroids, antimalarials, non-steroidal anti-inflammatory drugs (NSAIDs), and immunosuppressive...” NCT02885610 ↗106“During the study, subjects continued to receive 1 or more background non-biologic DMARDs (e.g. methotrexate, leflunomide) at the dose level(s) and regimen(s) administered at...” NCT00124982 ↗ “Patients on corticosteroids (plus conventional therapy) will be randomized to receive anakinra (Kineret®), or one of the following: methotrexate, azathioprine, leflunomide,...” NCT01033656 ↗ “Patients who receive standard-therapy (Sulphasalazine, Methotrexate, Leflunomide) are treated with common dosages of these drugs that are deduced from the common treatment of...” NCT00244179 ↗ “csDMARDs may include one or two of the following: methotrexate (MTX), hydroxychloroquine or chloroquine, sulfasalazine, and/or leflunomide (combination of leflunomide and MTX...” NCT02873936 ↗ “The following DMARDs were permitted in this study: methotrexate (MTX), chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00531817 ↗ “Disease-modifying anti-rheumatic drugs included methotrexate, chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide.” NCT00720798 ↗ “methotrexate 7.5-15 mg once weekly hydroxychloroquine 200 mg twice daily sulfasalazine 500 mg to 3 g once daily leflunomide 20 mg once daily” NCT05671497 ↗ “Methotrexate(MTX) and/or 1 DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01211834 ↗ “including Leflunomide，Hydroxychloroquine,Sulfasalazine,Azathioprine,Tripterygium glycosides and Total glucosides of paeony” NCT04066803 ↗ “Standard-of-care DMARD therapy, including methotrexate, sulfasalazine, leflunomide, minocycline, and/or hydroxychloroquine” NCT01313208 ↗ “including azathioprine, mycophenolate mofetil, cyclophosphamide, methotrexate, leflunomide, tacrolimus, cyclosporine.” NCT05247203 ↗ “DMARDs(chloroquine, hydroxychloroquine, parenteral gold, sulfasalazine, azathioprine, and leflunomide)” NCT01256736 ↗ “DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months.” NCT01600521 ↗ “Methotrexate or leflunomide + targeted therapy chosen by investigator” NCT02714634 ↗ “methotrexate, leflunomide, hydroxychloroquine or sulfasalazine” NCT05447520 ↗ “methotrexate, leflunomide, hydroxychloroquine or sulfasalazine” NCT03863405 ↗ “methotrexate- leflunomide- sulfasalazine- hydroxychloroquine” NCT06640309 ↗ “* Leflunomide - Weight based, 10-20 mg once daily” NCT05871086 ↗ “or Leflunomide (\<=20mg/d)” NCT04124861 ↗ “leflunomide(Arthfree®)” NCT06753565 ↗ |
| Known as | Arava | “Leflunomide (Arava) is an immunosuppressive drug, approved for the treatment of rheumatoid arthritis, and has been used in more than 300,000 patients worldwide.” NCT00684372 ↗1“Leflunomid (e.g. Arava®)” NCT02779114 ↗ |
| Known as | Arthfree | “leflunomide(Arthfree®)” NCT06753565 ↗ |
| Known as | HWA-486 | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | L04AA13 | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | LEF | “Leflunomide (LEF) is a derivative of isoxazole and is converted into an active metabolite which blocks de novo synthesis of pyrimidines in activated T lymphocytes, thereby...” NCT05113004 ↗5“one group was administered Xinfeng capsule (XFC) plus the placebo of leflunomide and the other given leflunomide (LEF) plus the placebo of XFC for twelve weeks.” PMID 26591677 ↗ Oct 2015 “DMARDs (methotrexate: MTX, leflunomide: LEF) were taken orally for at least 12 months.” NCT01600521 ↗ “Drug: Leflunomide(LEF)” NCT02532777 ↗ “ARM 2:Leflunomide(LEF)” NCT01659242 ↗ “Leflunomide(LEF)” NCT02981979 ↗ |
| Known as | Leflunomid | “Leflunomid (e.g. Arava®)” NCT02779114 ↗ |
| Known as | Leflunomida | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | Leflunomide medac | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | Leflunomide ratiopharm | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | Leflunomide teva | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | Leflunomide winthrop | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | Leflunomide zentiva (previously leflunomide winthrop) | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | NSC-677411 | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | NSC-759864 | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | Repso | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Known as | SU101 | “patients receive leflunomide (SU101) IV over 4-5 hours weekly for 12 weeks” NCT00004071 ↗3“Patients receive leflunomide (SU101) IV over 6 hours daily on days 1-4” NCT00003293 ↗ “Patients receive leflunomide (SU101) IV over 6 hours on days 1-4.” NCT00003775 ↗ |
| Known as | SULOL | ChEMBL registry synonym — accepted as the source's own label CHEMBL960 ↗ |
| Action | Inhibit | “SU101 is a member of a novel class of antineoplastic agents, platelet-derived growth factor (PDGF) receptor inhibitors.” NCT00001573 ↗ |
| Modality | Small molecule | “Leflunomide, an isoxazole derivative, has profound immunosuppressive activity.” NCT00001863 ↗ |
| Route | Intravenous | “Patients receive a 96 hour continuous IV infusion of SU101 on days 1-4.” NCT00001573 ↗ |
| Target | DHODH | “inhibitor of dihydroorotate dehydrogenase (DHODH)” NCT03709446 ↗ |